Status:
COMPLETED
A Dose Finding Study of TKM-080301 Infusion in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients
Lead Sponsor:
Arbutus Biopharma Corporation
Conditions:
Cancer
Neuroendocrine Tumors
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
This study will be a Phase I/II, open-label, non-randomized, dose-finding trial conducted at multiple clinical centers. The study is designed to determine the safety, tolerability and PK of TKM-080301...
Eligibility Criteria
Inclusion
- Patients must have a histologically and cytologically confirmed solid tumor that is refractory to standard therapy or for which no standard therapy is known to exist, or who are not candidates for standard therapy, or non-Hodgkin's lymphoma or Hodgkin's disease that is refractory to standard therapy (i.e., patients have relapsed following at least 2 prior therapies) or for which no standard therapy is known to exist. For the Neuroendocrine (NET) and adrenocortical carcinoma (ACC) expansion cohort subjects must have histologically or cytologically confirmed, measurable (per RECIST 1.1) NET or ACC tumor that is refractory to standard therapy or for which no standard therapy is known to exist, or who are not candidates for standard therapy.
- Patient has an ECOG performance status of 0 - 1,
- Patient has adequate hematologic, hepatic and renal function,
- Patient is seronegative for hepatitis B virus (HBV) and hepatitis C virus (HCV),
- Patients must have a life expectancy of at least 12 weeks.
Exclusion
- Unresolved toxicities (\> Grade 1) of previous chemotherapy,
- Patients with primary tumors of the central nervous system (CNS),
- Prophylactic hematologic growth factors administered \</= 2 weeks prior to start of therapy,
- Patient has history of or existing clinically significant cardiovascular disease,
- Patient has a history of clinically significant asthma or COPD requiring daily medication within the last 6 months,
- Patient has a seizure disorder not controlled on medication,
- Patient has a known or suspected viral, parasitic, or fungal infection,
- Patient has known hypersensitivity or previous severe reactions to oligonucleotide- or lipid-based products, including liposomal drug products and phospholipid-based products,
- Patient has been treated with any investigational drugs, biologics, or devices within 28 days prior to study treatment.
Key Trial Info
Start Date :
December 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2015
Estimated Enrollment :
68 Patients enrolled
Trial Details
Trial ID
NCT01262235
Start Date
December 1 2010
End Date
August 1 2015
Last Update
January 16 2019
Active Locations (8)
Enter a location and click search to find clinical trials sorted by distance.
1
Scottsdale Healthcare Research Institute
Scottsdale, Arizona, United States, 85258
2
Mayo Clinic Arizona
Scottsdale, Arizona, United States, 85259
3
Moffitt Cancer Center
Tampa, Florida, United States, 33612
4
University of Iowa/Holden Comprehensive Cancer Center
Iowa City, Iowa, United States, 52242